Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease
Finerenone significantly delayed kidney disease progression in patients with non-diabetic chronic ki...
Publisher
Germany
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Finerenone significantly delayed kidney disease progression in patients with non-diabetic chronic ki...
Source route
Continue on bayer.com
Leave the platform to read the original full article on the publisher site.
Source: Bayer Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
Notice Regarding the Consolidation of Shionogi‑Apnimed Sleep Science, LLC as a Subsidiary of Shionogi
Accelerating research and development toward establishing the sleep disorder field as one of Shionog...
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Swi...
GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan
Designation supported by early clinical data showing durable responses in certain types of small-cel...
Press releaseMar 23, 2026Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence…
New Rhapsido ® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontan...